RPH
Brand names,
RPH
Analogs
RPH
Brand Names Mixture
RPH
Chemical_Formula
C11H16N2O
RPH
RX_link
http://www.rxlist.com/cgi/generic3/tocainide.htm
RPH
fda sheet
RPH
msds (material safety sheet)
RPH
Synthesis Reference
No information avaliable
RPH
Molecular Weight
192.258 g/mol
RPH
Melting Point
246-266 oC
RPH
H2O Solubility
1.07E+004 mg/L
RPH
State
Solid
RPH
LogP
1.308
RPH
Dosage Forms
400 mg and 600 mg tablets for oral administration
RPH
Indication
For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
RPH
Pharmacology
Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.
RPH
Absorption
Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.
RPH
side effects and Toxicity
The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.
RPH
Patient Information
RPH
Organisms Affected
Humans and other mammals